Using pharmacogenomics to personalise drug therapy: which drugs, when and how
Australian Prescriber · 10.06.2025 · 48 (3) · 82-86
DOI: 10.18773/austprescr.2025.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Australian Prescriber, online erschienen am 10.06.2025. Verfasst von Sophie L Stocker und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pharmacogenomic testing provides information on whether a patient possesses gene variants that can influence drug exposure or response. It can be used as part of clinical decision-making to personalise drug therapy. Pharmacogenomic testing can help identify patients at higher risk of serious adverse drug reactions or therapeutic failure, and sometimes it can explain unexpected adverse effects or poor efficacy in patients already on drug therapy. As drug responses are influenced by many factors, pharmacogenomic test results must always be interpreted in the clinical context of the patient. At the time of writing, tests for thiopurine methyltransferase (TPMT) (azathioprine, mercaptopurine, thioguanine) and human leucocyte antigen B*57:01 (abacavir) are Medicare-rebated. Pharmacogenomic testing is also recommended for several other drugs, such as allopurinol and clopidogrel, but these do not currently attract a Medicare rebate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney.
- Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney.
- St Vincent's Clinical Campus, Faculty of Medicine, University of New South Wales, Sydney.
- Centre for Medicines Use and Safety, Monash University, Melbourne.
- CMAX Clinical Research, Adelaide.
ORCID-Profile: Sophie L Stocker, Thomas M Polasek
Zitieren
APA
Stocker, S. L., & Polasek, T. M. (2025). Using pharmacogenomics to personalise drug therapy: which drugs, when and how. Australian Prescriber, 48(3), 82-86. https://doi.org/10.18773/austprescr.2025.021
Vancouver
Stocker SL, Polasek TM. Using pharmacogenomics to personalise drug therapy: which drugs, when and how. Australian Prescriber. 2025;48(3):82-86. doi:10.18773/austprescr.2025.021
BibTeX
@article{Stocker2025,
author = {Stocker, Sophie L and Polasek, Thomas M},
title = {Using pharmacogenomics to personalise drug therapy: which drugs, when and how},
journal = {Australian Prescriber},
year = {2025},
volume = {48},
number = {3},
pages = {82--86},
doi = {10.18773/austprescr.2025.021}
}
EUVIMED